WallStSmart

Mereo BioPharma Group PLC ADR (MREO)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Revolution Medicines Inc generates 48% more annual revenue ($742,000 vs $500,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. MREO earns a higher WallStSmart Score of 25/100 (F).

MREO

Avoid

25

out of 100

Grade: F

Growth: 3.3Profit: 2.5Value: 5.0Quality: 5.8
Piotroski: 4/9Altman Z: -12.28

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MREO1 strengths · Avg: 8.0/10
Price/BookValuation
1.6x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

MREO4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$49.99M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MREO

The strongest argument for MREO centers on Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : MREO

The primary concerns for MREO are Revenue Growth, EPS Growth, Market Cap.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

MREO is growing revenue faster at 0.0% — sustainability is the question.

MREO generates stronger free cash flow (-5M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MREO scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Mereo BioPharma Group PLC ADR

HEALTHCARE · BIOTECHNOLOGY · USA

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops and markets therapeutic products for the treatment of oncology and rare diseases in the UK and internationally. The company is headquartered in London, the United Kingdom.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?